Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Anika Therapeutics, Inc.

ANIK · Nasdaq · CIK 0000898437 · Healthcare · Drug Manufacturers—Specialty & Generic

INSIDER SIGNAL

58.5 / 100

3 buyers · 4 purchase transaction lines · $264.3K gross purchase

WHY THIS SIGNAL?

Buyer breadthModerate
Purchase sizeModerate
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+21.0 / 35
Purchase size+11.7 / 25
Role+13.0 / 20
Recency+2.9 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 3 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Role scores low · most senior buyer: President and CEO (CEO, chair and 10% owners score lowest)
  • ⚠ Purchase activity is becoming less recent

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Fischetti Gary PDirector
○●●
Griffin Stephen D.President and CEO
●○○
HENNEMAN JOHN B IIIDirector
●○
Richard StephenDirector
○
Capper Joseph HDirector
○
CONLEY SHERYL LDirector
○
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS3
PURCHASE CONCENTRATION57%Largest buyer: Griffin Stephen D. · $149.9K
CLUSTER BUYING · 15D2 insidersPeak activity: 2026-04-30–2026-05-01

Roles in the peak window: Director, President and CEO. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

58.5 / 100

Latest recorded score

↓ -0.2 ptsversus the previous recorded snapshot
  1. 58.9
  2. 58.9
  3. 58.8
  4. 58.7
  5. 58.5

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

4Purchases
0Sales
31Other Form 4 lines
16SEC filings · 365 days
BUYING4 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER7 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-6.7%
3M
+24.2%
6M
+32.7%
12M
+111.9%

Volatility & liquidity

Volatility
55.9%
Beta
0.20
Avg daily value
USD 1.9M

Valuation

Market cap
USD 262.0M
P/E
—

Fundamentals

Profit margin
-9.8%
ROE
-7.7%
Industry
Drug Manufacturers—Specialty & Generic

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance · From SEC filings: Market cap, Profit margin, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-07-24 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
367,155
Previous report
381,376
Avg daily volume
83,024
Days to cover
4.4

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-04Fischetti Gary PPurchase (P)Common Stock1,000USD 20.32USD 20,320SEC filing ↗
2026-08-03Fischetti Gary PPurchase (P)Common Stock1,000USD 20.75USD 20,750SEC filing ↗
2026-05-01HENNEMAN JOHN B IIIPurchase (P)Common Stock5,000USD 14.66USD 73,300SEC filing ↗
2026-04-30Griffin Stephen D.Purchase (P)Common Stock12,200USD 12.29USD 149,938SEC filing ↗
2022-05-11Colleran DavidPurchase (P)Common Stock1,500USD 21.37USD 32,055SEC filing ↗
2022-03-14Colleran DavidPurchase (P)Common Stock1,500USD 26.65USD 39,975SEC filing ↗
2022-03-11Thompson Jeffery SPurchase (P)Common Stock2,000USD 24.66USD 49,320SEC filing ↗
2022-03-11Levitz Michael LPurchase (P)Common Stock4,000USD 24.62USD 98,480SEC filing ↗
2022-03-11Blanchard Cheryl RPurchase (P)Common Stock8,100USD 25.57USD 207,132SEC filing ↗
2021-08-12Levitz Michael LPurchase (P)Common Stock777USD 40.21USD 31,243SEC filing ↗
2021-08-11Levitz Michael LPurchase (P)Common Stock2,850USD 40.21USD 114,598SEC filing ↗
2021-05-18HENNEMAN JOHN B IIIPurchase (P)Common Stock2,000USD 42.86USD 85,720SEC filing ↗

Form 4 evidence

35 transaction lines in the latest 365-day window; 194 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-04Fischetti Gary PPurchase (P)Common Stock1,000USD 20.32USD 20,320SEC filing ↗
2026-08-03Fischetti Gary PPurchase (P)Common Stock1,000USD 20.75USD 20,750SEC filing ↗
2026-06-18Richard StephenAward / grant (A)Common Stock10,402USD 0.00USD 0SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-04Fischetti Gary PPurchase (P)Common Stock1,000USD 20.32USD 20,320SEC filing ↗
2026-08-03Fischetti Gary PPurchase (P)Common Stock1,000USD 20.75USD 20,750SEC filing ↗
2026-06-18Richard StephenAward / grant (A)Common Stock10,402USD 0.00USD 0SEC filing ↗
2026-06-18HENNEMAN JOHN B IIIAward / grant (A)Common Stock10,402USD 0.00USD 0SEC filing ↗
2026-06-18Fischetti Gary PAward / grant (A)Common Stock10,402USD 0.00USD 0SEC filing ↗
2026-06-18Capper Joseph HAward / grant (A)Common Stock10,402USD 0.00USD 0SEC filing ↗
2026-06-18CONLEY SHERYL LAward / grant (A)Common Stock10,402USD 0.00USD 0SEC filing ↗
2026-06-03Griffin Stephen D.Option exercise / conversion (M)Common Stock12,840USD —USD —SEC filing ↗
2026-06-03Griffin Stephen D.Tax withholding (F)Common Stock3,769USD 14.41USD 54,311SEC filing ↗
2026-05-01HENNEMAN JOHN B IIIPurchase (P)Common Stock5,000USD 14.66USD 73,300SEC filing ↗
2026-04-30Griffin Stephen D.Purchase (P)Common Stock12,200USD 12.29USD 149,938SEC filing ↗
2026-03-15McLeod IanOption exercise / conversion (M)Common Stock2,658USD —USD —SEC filing ↗
2026-03-15McLeod IanTax withholding (F)Common Stock781USD 14.20USD 11,090SEC filing ↗
2026-03-15Colleran DavidOption exercise / conversion (M)Common Stock6,449USD —USD —SEC filing ↗
2026-03-15Colleran DavidTax withholding (F)Common Stock1,893USD 14.20USD 26,881SEC filing ↗
2026-03-15Blanchard Cheryl ROption exercise / conversion (M)Common Stock25,131USD —USD —SEC filing ↗
2026-03-15Blanchard Cheryl RTax withholding (F)Common Stock12,104USD 14.20USD 171,877SEC filing ↗
2026-03-14McLeod IanOption exercise / conversion (M)Common Stock3,774USD —USD —SEC filing ↗
2026-03-14McLeod IanTax withholding (F)Common Stock1,449USD 14.20USD 20,576SEC filing ↗
2026-03-14McLeod IanAward / grant (A)Common Stock1,161USD 0.00USD 0SEC filing ↗
2026-03-14Griffin Stephen D.Option exercise / conversion (M)Common Stock12,824USD —USD —SEC filing ↗
2026-03-14Griffin Stephen D.Tax withholding (F)Common Stock5,944USD 14.20USD 84,405SEC filing ↗
2026-03-14Griffin Stephen D.Award / grant (A)Common Stock6,412USD 0.00USD 0SEC filing ↗
2026-03-14Colleran DavidOption exercise / conversion (M)Common Stock9,388USD —USD —SEC filing ↗
2026-03-14Colleran DavidTax withholding (F)Common Stock4,168USD 14.20USD 59,186SEC filing ↗
2026-03-14Colleran DavidAward / grant (A)Common Stock4,694USD 0.00USD 0SEC filing ↗
2026-03-14Blanchard Cheryl ROption exercise / conversion (M)Common Stock24,519USD —USD —SEC filing ↗
2026-03-14Blanchard Cheryl RTax withholding (F)Common Stock14,728USD 14.20USD 209,138SEC filing ↗
2026-03-14Blanchard Cheryl RAward / grant (A)Common Stock24,520USD 0.00USD 0SEC filing ↗
2026-03-09McLeod IanOption exercise / conversion (M)Common Stock2,197USD —USD —SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerANIK
CIK0000898437
SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic Yahoo Finance
SEC SIC3841 Surgical & Medical Instruments & Apparatus
ExchangeNasdaq

Data coverage

Local Form 4 history194 transaction lines from 2020-02-04 to 2026-08-04
13 P purchase lines · 4 S sale lines · 177 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.